-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Renal cell carcinoma (renal cancer for short) is a highly malignant tumor in the urinary system and one of the most common tumors.
The ATLAS trial, which evaluated the efficacy of adjuvant axitinib versus placebo for renal cell carcinoma (RCC), was stopped because the planned interim analysis indicated that it was invalid.
This article reports the results of the subgroup analysis of the trial by race, duration of treatment, dose adjustment, and toxicity.
DFS in high-risk patients
DFS in high-risk patientsNeither Asian nor non-Asian people have observed a disease-free survival (DFS) benefit from axitinib or placebo treatment .
No disease-free survival (DFS) benefit was observed from either Asian or non-Asian treatment with Axitinib or placebo .
DFS in subgroup patients vs non-Asian patients
DFS in subgroup patients vs non-Asian patientsCompared with non-Asian patients, Asian patients treated with Axitinib had a higher proportion of invoking drug doses due to adverse reactions (AE) (58.
In Asian patients, proteinuria, hypothyroidism, nasopharyngitis, and hypertension are more common in Japanese patients than in Korean patients, and more common in Korean patients than in Chinese patients .
Proteinuria, hypothyroidism, nasopharyngitis and hypertension are more common in Japanese patients than in Korean patients, and more common in Korean patients than in Chinese patients
DFS in patients with reduced dose of axitinib vs.
DFS in patients with reduced dose of axitinib vs.
Compared with patients treated with a stable dose of Axitinib, patients with a dose reduction had a longer DFS Compared with patients treated with a stable dose of Axitinib, patients with a dose reduction had a longer DFS
In summary, the subgroup analysis of Asian patients vs.
The duration of treatment does not affect DFS.
Original source:
Quinn DI,Ng CF,Grande E et al.
org/10.
1016/j.
esmoop.
2021.
100105" target="_blank" rel="noopener">ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups in this message
